Sorafenib for Treatment of Hepatocellular Carcinoma: A Systematic Review (original) (raw)
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. ArticlePubMed Google Scholar
Pons-Renedo F, Llovet JM. Hepatocellular carcinoma: a clinical update. Med Gen Med. 2003;5:11. Google Scholar
American Cancer Society. Cancer Facts and Figures 2010. Atlanta: American Cancer Society; 2010. Google Scholar
El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37:S88–S94. ArticlePubMed Google Scholar
El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817–823. PubMed Google Scholar
El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750. ArticlePubMedCAS Google Scholar
Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/stat pathways in human HCC. Gastroenterology. 2006;130:1117–1128. ArticlePubMedCAS Google Scholar
Marotta F, Vangieri B, Cecere A, et al. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Clin Ter. 2004;155:187–199. PubMedCAS Google Scholar
Avila MA, Berasain C, Sangro B, et al. New therapies for hepatocellular carcinoma. Oncogene. 2006;25:3866–3884. ArticlePubMedCAS Google Scholar
Goodsell DS. The molecular perspective: the Ras oncogene. Oncologist. 1999;4:263–264. PubMedCAS Google Scholar
Stockl L, Berting A, Malkowski B, et al. Integrity of c-Raf-1/MEK signal transduction cascade is essential for hepatitis B virus gene expression. Oncogene. 2003;22:2604–2610. ArticlePubMed Google Scholar
Giambartolomei S, Covone F, Levrero M, et al. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein. Oncogene. 2001;20:2606–2610. ArticlePubMedCAS Google Scholar
Shimotohno K, Watashi K, Tsuchihara K, et al. Hepatitis C virus and its roles in cell proliferation. J Gastroenterol. 2002;37:50–54. ArticlePubMedCAS Google Scholar
Gollob JA, Wilhelm S, Carter C, et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 2006;33:392–406. ArticlePubMedCAS Google Scholar
Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109. ArticlePubMedCAS Google Scholar
Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129–3140. ArticlePubMedCAS Google Scholar
Rahmani M, Davis EM, Bauer C, et al. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005;280:35217–35227. ArticlePubMedCAS Google Scholar
Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005;24:6861–6869. ArticlePubMedCAS Google Scholar
Molhoek KR, Griesemann H, Shu J, et al. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res. 2008;68:4392–4397. ArticlePubMedCAS Google Scholar
Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol. 2008;61:535–548. ArticlePubMedCAS Google Scholar
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. ArticlePubMed Google Scholar
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. ArticlePubMedCAS Google Scholar
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. ArticlePubMedCAS Google Scholar
Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293–4300. ArticlePubMedCAS Google Scholar
Massa E, Stadier C, et al. Efficacy, safety and impact on quality of life of a treatment with sorafenib in elderly cancer patients with advanced hepatocellular carcinoma. Result of a phase II study. Ann Oncol. 2009;20:s65. Google Scholar
Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer. 2009;115:428–436. ArticlePubMedCAS Google Scholar
Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2008;99:159–165. PubMedCAS Google Scholar
Castroagudin JF, Molina E, et al. Short-term efficacy and safety of treatment of advanced hepatocellular carcinoma with sorafenib. J Hepatol. 2008;48:s141–s142. Google Scholar
Prete SD, Montella L, Caraglia M, et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So LAR.study. Cancer Chemother Pharmacol. 2010;66:837–844. ArticlePubMed Google Scholar
Petrini I, Muul LM, et al. A phase II trial of sorafenib in combination with 5-fluorouracil continuous infusion in patients with advanced hepatocellular carcinoma: preliminary data. J Clin Oncol. 2009;27:4592. Google Scholar
Gianluca D, Muul LM, et al. Prospective phase II study of combination sorafenib plus mitomycin-c in the treatment of advanced hepatocellular carcinoma. Ann Oncol. 2009;20:8. Google Scholar
Yau T, Chan P, et al. Phase II trial of sorafenib with capecitabine and oxaliplatin (SECOX) in patients with locally advanced or metastatic hepatocellular carcinoma. EJC Suppl. 2009;7:20–21. Article Google Scholar
Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304:2154–2160. ArticlePubMedCAS Google Scholar
Hsu CH, Shen YC, Lin ZZ, et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol. 2010;53:126–131. ArticlePubMedCAS Google Scholar
Giuliana F, Rosenberg A, et al. Sorafenib plus cisplatin and gemcitabine in the treatment of advanced hepatocellular carcinoma: a phase II study by the Grupo Oncologico Dell’Italia Meridonale (PROT. GOIM 2705). Cancer Treat Rev. 2010;36:S96. Google Scholar
Erhardt A, Kollings F, et al. First-in-men demonstration of sorafenib plus TACE for the treatment of advanced hepatocellular carcinoma (SOCRATES trial). Hepatology. 2009;50:1080A. Google Scholar
Reyes DK, Azad N, et al. Phase II trial of sorafenib wit doxirubicin eluting bead-transarterial chemoembolization (DEB–TACE) for patients with hepatocellular carcinoma: interim safety and efficacy analysis. Hepatology. 2009;50:6A–7A. Google Scholar
Richly H, Schultheis B, Adamietz IA, et al. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer. 2009;45:579–587. ArticlePubMedCAS Google Scholar
Faivre S, Feng L, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of AVE 1642, a human monoclonal antibody inhibiting the insulin-like grouth factor-1 receptor (IGF-1R/CD221), administered as single agent and in combination with sorafinib as first line therapy in patients with advanced hepatocellular carcinoma. Hepatology. 2010;52:S 466A–288.
Dufour JF, Hoppe H, Heim MH, et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist. 2010;15:1198–1204. ArticlePubMedCAS Google Scholar
Pinter M, Smith W, et al. An interim safety analysis of sorafenib plus transarterial chemoembolization in hepatocellular carcinoma—a phase I/II pilot study (SORATACE-1 trial). Hepatology. 2010;52:1157A–1759. Google Scholar
Pawlik TM, Reyes DK, Cosgrove D, et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011;29:3960–3967. ArticlePubMedCAS Google Scholar
Yang CH, Lin WC, Chuang CK, et al. Hand–foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158:592–596. ArticlePubMedCAS Google Scholar
Chan AO, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002;94:1747–1752. ArticlePubMed Google Scholar
Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxic may mediate hypoxic-initiated angiogenesis. Nature. 1992;359:843–845. ArticlePubMedCAS Google Scholar
Li X, Feng GS, Zheng CS, et al. Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study. World J Gastroenterol. 2003;9:2445–2449. PubMedCAS Google Scholar
Lee JK, Chung YH, et al. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol. 2002;17:52–58. ArticlePubMed Google Scholar